Have a feature idea you'd love to see implemented?
Let us know!
XCUR Exicure Inc
Price (delayed)
$17.25
Market cap
$37.47M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
$42.56M
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes its proprietary
Highlights
The net income has soared by 51% since the previous quarter
The quick ratio has grown by 44% from the previous quarter and by 10% YoY
Exicure's EPS has plunged by 120% YoY but it has soared by 54% from the previous quarter
XCUR's revenue has dropped by 98% year-on-year
XCUR's gross profit has dropped by 98% year-on-year
Key stats
What are the main financial stats of XCUR
Market
Valuations
Earnings
Shares outstanding
2.17M
Market cap
$37.47M
Enterprise value
$42.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
19.32
Price to sales (P/S)
65.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.12
Revenue
$500,000
Gross profit
$500,000
Net income
-$4.01M
EBIT
-$3.98M
EBITDA
-$3.17M
Free cash flow
-$2.17M
Per share
Balance sheet
Liquidity
EPS
-$2.07
EPS diluted
-$2.07
Free cash flow per share
-$1.14
Book value per share
$0.89
Revenue per share
$0.26
TBVPS
$5.6
Total assets
$10.63M
Total liabilities
$9.09M
Debt
$5.43M
Equity
$1.55M
Working capital
-$1.06M
Debt to equity
3.52
Current ratio
0.71
Quick ratio
0.46
Net debt/EBITDA
-1.6
Margins
Efficiency
Dividend
EBITDA margin
-634.4%
Gross margin
100%
Net margin
-801.4%
Operating margin
-1,228.2%
Return on assets
-36.8%
Return on equity
-190.9%
Return on invested capital
-29.9%
Return on capital employed
-57.1%
Return on sales
-796.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XCUR stock price
How has the Exicure stock price performed over time
Intraday
0.41%
1 week
9.59%
1 month
-37.7%
1 year
469.31%
YTD
494.83%
QTD
397.12%
Financial performance
How have Exicure's revenue and profit performed over time
Revenue
$500,000
Gross profit
$500,000
Operating income
-$6.14M
Net income
-$4.01M
Gross margin
100%
Net margin
-801.4%
XCUR's revenue has dropped by 98% year-on-year
XCUR's gross profit has dropped by 98% year-on-year
The net margin has soared by 51% from the previous quarter
The net income has soared by 51% since the previous quarter
Growth
What is Exicure's growth rate over time
Valuation
What is Exicure stock price valuation
P/E
N/A
P/B
19.32
P/S
65.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.12
Exicure's EPS has plunged by 120% YoY but it has soared by 54% from the previous quarter
XCUR's equity has dropped by 66% year-on-year and by 4.2% since the previous quarter
XCUR's revenue has dropped by 98% year-on-year
Efficiency
How efficient is Exicure business performance
Exicure's ROS has soared by 51% from the previous quarter
The ROA has grown by 48% from the previous quarter
Exicure's ROIC has increased by 48% from the previous quarter
XCUR's ROE is up by 34% QoQ
Dividends
What is XCUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XCUR.
Financial health
How did Exicure financials performed over time
The company's total assets is 17% higher than its total liabilities
Exicure's current ratio has decreased by 49% YoY but it has increased by 16% from the previous quarter
The quick ratio has grown by 44% from the previous quarter and by 10% YoY
Exicure's debt to equity has surged by 153% YoY but it has decreased by 15% QoQ
XCUR's equity has dropped by 66% year-on-year and by 4.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.